These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24888356)

  • 1. Incorporating external evidence in trial-based cost-effectiveness analyses: the use of resampling methods.
    Sadatsafavi M; Marra C; Aaron S; Bryan S
    Trials; 2014 Jun; 15():201. PubMed ID: 24888356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-level resampling as a novel method for the calculation of the expected value of sample information in economic trials.
    Sadatsafavi M; Marra C; Bryan S
    Health Econ; 2013 Jul; 22(7):877-82. PubMed ID: 22933363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapolation of Survival Curves from Cancer Trials Using External Information.
    Guyot P; Ades AE; Beasley M; Lueza B; Pignon JP; Welton NJ
    Med Decis Making; 2017 May; 37(4):353-366. PubMed ID: 27681990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival time outcomes in randomized, controlled trials and meta-analyses: the parallel universes of efficacy and cost-effectiveness.
    Guyot P; Welton NJ; Ouwens MJ; Ades AE
    Value Health; 2011; 14(5):640-6. PubMed ID: 21839400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis using data from multinational trials: the use of bivariate hierarchical modeling.
    Manca A; Lambert PC; Sculpher M; Rice N
    Med Decis Making; 2007; 27(4):471-90. PubMed ID: 17641141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap.
    Barber JA; Thompson SG
    Stat Med; 2000 Dec; 19(23):3219-36. PubMed ID: 11113956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial factorial trials: comparing methods for statistical analysis and economic evaluation.
    Dakin HA; Gray AM; MacLennan GS; Morris RW; Murray DW
    Trials; 2018 Aug; 19(1):442. PubMed ID: 30115104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-parametric methods for cost-effectiveness analysis: the central limit theorem and the bootstrap compared.
    Nixon RM; Wonderling D; Grieve RD
    Health Econ; 2010 Mar; 19(3):316-33. PubMed ID: 19378353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing and comparing costs: how robust are the bootstrap and methods based on asymptotic normality?
    O'Hagan A; Stevens JW
    Health Econ; 2003 Jan; 12(1):33-49. PubMed ID: 12483759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Building a Bayesian bridge from evidence to guidelines.
    Goodman SN
    Arch Intern Med; 2009 Aug; 169(15):1436-7. PubMed ID: 19667309
    [No Abstract]   [Full Text] [Related]  

  • 11. Choice of statistical model for cost-effectiveness analysis and covariate adjustment: empirical application of prominent models and assessment of their results.
    Mantopoulos T; Mitchell PM; Welton NJ; McManus R; Andronis L
    Eur J Health Econ; 2016 Nov; 17(8):927-938. PubMed ID: 26445961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A framework for cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW
    Health Econ; 2001 Jun; 10(4):303-15. PubMed ID: 11400253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cluster randomized trials: another problem for cost-effectiveness ratios.
    Flynn TN; Peters TJ
    Int J Technol Assess Health Care; 2005; 21(3):403-9. PubMed ID: 16110722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporating considerations of cost-effectiveness, affordability, and resource implications in guideline development: article 6 in Integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report.
    Hill SR; Olson LG; Falck-Ytter Y; Cruz AA; Atkins D; Baumann M; Jaeschke R; Woitalla T; Schünemann HJ;
    Proc Am Thorac Soc; 2012 Dec; 9(5):251-5. PubMed ID: 23256167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian hierarchical models for cost-effectiveness analyses that use data from cluster randomized trials.
    Grieve R; Nixon R; Thompson SG
    Med Decis Making; 2010; 30(2):163-75. PubMed ID: 19675321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size determination for cost-effectiveness trials.
    Willan AR
    Pharmacoeconomics; 2011 Nov; 29(11):933-49. PubMed ID: 21988292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How valuable are multiple treatment comparison methods in evidence-based health-care evaluation?
    Cooper NJ; Peters J; Lai MC; Juni P; Wandel S; Palmer S; Paulden M; Conti S; Welton NJ; Abrams KR; Bujkiewicz S; Spiegelhalter D; Sutton AJ
    Value Health; 2011; 14(2):371-80. PubMed ID: 21296599
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian cost-effectiveness analysis from clinical trial data.
    O'Hagan A; Stevens JW; Montmartin J
    Stat Med; 2001 Mar; 20(5):733-53. PubMed ID: 11241573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporating individual historical controls and aggregate treatment effect estimates into a Bayesian survival trial: a simulation study.
    Brard C; Hampson LV; Gaspar N; Le Deley MC; Le Teuff G
    BMC Med Res Methodol; 2019 Apr; 19(1):85. PubMed ID: 31018832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.